Skip to main content

FDA and Other Compliance Considerations in Remote Promotion, Training and Medical Information Services

Addressing Challenges and Mitigating Risks During the COVID-19 Pandemic and Beyond

May 13, 2020
Arnold & Porter Webinar Series: Pharma 3.0

Life sciences companies are doing their best to conduct business through remote customer interactions, and many expect that the expanded use of such technologies will persist well beyond the current public health emergency. While the life sciences industry can address many healthcare practitioner (HCP) and patient needs in this manner, the general rules, guidance and codes governing such interactions were not necessarily written with remote interactions in mind. Thus, enforcement risks may emerge in the absence of careful planning and strong safeguards.

This webinar in our Pharma 3.0 series delves into these issues to (1) identify the potential legal, regulatory and compliance risks; and (2) provide practical considerations for planning and successful implementation. Topics include promotion via WebEx, Zoom®, and similar platforms; considerations for virtual sales and medical information personnel; and healthcare compliance risks and best practices.

To help our clients navigate the coronavirus (COVID-19) crisis, Arnold & Porter has established a Coronavirus Task Force covering a wide range of issues and challenges. Subscribe to our "Coronavirus (COVID-19)" mailing list to receive our latest client Advisories and register for upcoming webinars.

Meet the Speakers

Daniel A. Kracov
Arnold & Porter
Mahnu V. Davar
Arnold & Porter
Nancy L. Perkins
Arnold & Porter
Abraham Gitterman
Senior Associate
Arnold & Porter